| Project/Area Number |
17591207
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Psychiatric science
|
|---|
| Research Institution | Nagoya University |
|---|
Principal Investigator |
UMEGAKI Hiroyuki Nagoya University, University Hospital, Assistant Professor (40345898)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SUZUKI Yusuke Nagoya University, Granduate school of Medicine, Designated assistant Professor (90378167)
AKATSU Hnroyasu Fukushimura Hosipital, Choju Medical Institute, Vice-director (00399734)
|
|---|
| Project Period (FY) |
2005 – 2007
|
| Project Status |
Completed (Fiscal Year 2007)
|
| Budget Amount *help |
¥3,730,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥330,000)
Fiscal Year 2007: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2006: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 2005: ¥1,300,000 (Direct Cost: ¥1,300,000)
|
|---|
| Keywords | dopamine / acetylcholine / cognitive function / dementia with Lewv bodies / Alzheimer's disease / hippocampus / institution placement / motor function / 中隔核 / 対角核 |
|---|
| Research Abstract |
In the current study we investigated the pathophysiology of dementia with Lewy bodies (DLB) to explore the new strategy of treatment of this disease. What we have shown are below.
1, By studying the autopsy brains of patients with DLB and Alzheimer's disease (AD), we found that at admission to residential hallucinations, impaired wakefulness, impairment of activities of daily living and emotional disturbance were more frequent at admission in DLB patients than in AD patients. Moreover, DLB patients had higher scores in the cognitive test at admission and shorter time from onset of dementia to institutionalization than did AD patients.
2, DLB patients have severer impairment of the cholinergic neurons projecting to the hippocampus compared to the normal elderly and patients with AD.
3, By using the animal models with memory impairment induced by the cholinergic neuronal dysfunction, the injection of dopamine agonists into the hippocampus ameliorated the memory impairment.
Taken all these together we demonstrated that DLB is a disease that is very distinguished from Alzheimer's disease in terms of disease course and care burden and the dual therapy strategy to enhance both cholinergic and dopaminergic neuronal systems has relevance. We have started the combination therapy with L-dopa and cholinesterase inhibitior for DLB. Four DLB patients have taken treatment with L-dopa (62.8mg/day) for 3 month. So far we have not reached the conclusion on the efficacy of this treatment because of the small number of the patients involved
|
